Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19812674 | 0.83 | EPHX1 (0.50) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL1335896 | 0.79 | SHBG (0.41) | EPHX1TP53KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6988843 | 0.76 | SHBG (0.39) | EPHX1SHBG | |
| SCHEMBL7458138 | 0.75 | SHBG (0.38) | EPHX1SHBG | |
| SCHEMBL12987447 | 0.74 | SHBG (0.50) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL741065 | 0.74 | SHBG (0.50) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL7463334 | 0.73 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7457424 | 0.73 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7457530 | 0.73 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7452808 | 0.73 | TSHR (0.38) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340026-A1 | COMPOUNDS | NEW PHARMA LICENCE HOLDINGS LTD (MT) | 2023-10-26 | — | — | US | disclosed |
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20180030092-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | EPHX1 4404/4885TP53 3079/4885KDM4E 3352/4885 |
| US-20230340026-A1 | COMPOUNDS | BCAT1, BCAT2, CCNT1 | EPHX1 3764/4885TP53 1956/4885KDM4E 4030/4885 |
| US-20180030092-A1 | COMPOUNDS | BCAT1, BCAT2, IL4I1 | EPHX1 3597/4885TP53 1950/4885KDM4E 3533/4885 |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | EPHX1 4492/4885TP53 2947/4885KDM4E 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.